glp 1 face changes Ozempic face: what it is, how to treat it Exclusive | People with 'Ozempic

Clinical trials of semaglutide and tirzepatide documented yeast infections in 13% of participants, with higher rates in women

Yes, uniquely among peptides, BPC-157 has demonstrated high stability in gastric environments and is frequently researched orally, specifically for gastrointestinal tract injuries

At ACR Convergence 2025, researchers from Toronto and NYU reported that PsA patients starting GLP-1 receptor agonists had significant improvements in joint counts, CRP, pain scores, and DAPSA disease activity scores within one year of treatment. Whats interesting is that you dont seem to need a large dose to see these benefits

These findings have led to NICE recommendations supporting the use of certain GLP-1 receptor agonists in patients with type 2 diabetes and established cardiovascular disease or at high cardiovascular risk